{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:44:38Z","timestamp":1771998278333,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jocn.2020.01.067","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T20:14:10Z","timestamp":1582143250000},"page":"247-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)"],"prefix":"10.1016","volume":"74","author":[{"given":"Anna","family":"Shalman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiri","family":"Savir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Mechnik Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Ovanyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Boniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Bichovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Zlotnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moti","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeni","family":"Brotfain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jocn.2020.01.067_b0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mayocp.2016.12.002","article-title":"Guillain-Barre Syndrome","volume":"92","author":"Wijdicks","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.jocn.2020.01.067_b0010","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jocn.2020.01.067_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001798.pub2","article-title":"Plasma exchange for Guillain-Barre syndrome","author":"Raphael","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jocn.2020.01.067_b0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barre syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2020.01.067_b0025","article-title":"Second IVIg Course in Guillain-Barre Syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial","volume":"27","author":"Walgaard","year":"2018","journal-title":"J Peripher Nerv Syst"},{"issue":"10045","key":"10.1016\/j.jocn.2020.01.067_b0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jocn.2020.01.067_b0035","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"issue":"6 Pt 2","key":"10.1016\/j.jocn.2020.01.067_b0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lpm.2013.02.328","article-title":"Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS)","volume":"42","author":"van Doorn","year":"2013","journal-title":"Presse Med"},{"issue":"3","key":"10.1016\/j.jocn.2020.01.067_b0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.MAT.0000065465.52748.BB","article-title":"Hypoalbuminemia is a marker of overhydration in chronic maintenance patients on dialysis","volume":"49","author":"Dumler","year":"2003","journal-title":"ASAIO J"},{"issue":"9","key":"10.1016\/j.jocn.2020.01.067_b0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00007611-199809000-00009","article-title":"Admission serum albumin level and length of hospitalization in elderly patients","volume":"91","author":"Marinella","year":"1998","journal-title":"South Med J"},{"key":"10.1016\/j.jocn.2020.01.067_b0055","unstructured":"Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship? November 2017. (- 1555-9823 (Electronic); - 0003-1348 (Linking))."},{"issue":"2","key":"10.1016\/j.jocn.2020.01.067_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1371\/journal.pone.0192703","article-title":"FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barre syndrome","volume":"13","author":"Islam","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jocn.2020.01.067_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12883-017-0982-3","article-title":"The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barre syndrome: a retrospective study","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2020.01.067_b0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4049\/jimmunol.1502100","article-title":"Expression of early growth response gene-2 and regulated cytokines correlates with recovery from Guillain-Barre Syndrome","volume":"196","author":"Doncel-Perez","year":"2016","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jocn.2020.01.067_b0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of albumin levels with outcome in intravenous immunoglobulin-treated guillain-barre syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586819321654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586819321654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:21:09Z","timestamp":1760822469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586819321654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":15,"alternative-id":["S0967586819321654"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2020.01.067","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2020.01.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}